Sarepta Therapeutics, Inc.
SRPT· Nasdaq
SRPTSarepta Therapeutics, Inc.
Filed May 2, 2023 · 10-Q · 32 days after period end · 0000950170-23-016654
| Metric | Q1 2023 | Q1 2022 | Q1 2021 | Q1 2020 |
|---|---|---|---|---|
| Revenue | $231.50M | $188.83M | $124.93M | $100.45M |
| Net Income | -$516.76M | -$105.03M | -$167.25M | -$17.49M |
| EPS Diluted | -$5.86 | -$1.20 | -$2.10 | -$0.23 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sarepta Therapeutics, Inc. · CIK 873303 · Engraved from SEC EDGAR
ended Mar 31, 2023 · filed May 2, 2023 · 32 d after period end
